Cargando…
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial
PURPOSE: In the phase II DIRECT study a fasting mimicking diet (FMD) improved the clinical response to neoadjuvant chemotherapy as compared to a regular diet. Quality of Life (QoL) and illness perceptions regarding the possible side effects of chemotherapy and the FMD were secondary outcomes of the...
Autores principales: | Lugtenberg, Rieneke T., de Groot, Stefanie, Kaptein, Ad A., Fischer, Maarten J., Kranenbarg, Elma Meershoek-Klein, Carpentier, Marjolijn Duijm-de, Cohen, Danielle, de Graaf, Hiltje, Heijns, Joan B., Portielje, Johanneke E. A., van de Wouw, Agnes J., Imholz, Alex L. T., Kessels, Lonneke W., Vrijaldenhoven, Suzan, Baars, Arnold, Fiocco, Marta, van der Hoeven, Jacobus J. M., Gelderblom, Hans, Longo, Valter D., Pijl, Hanno, Kroep, Judith R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921018/ https://www.ncbi.nlm.nih.gov/pubmed/33179154 http://dx.doi.org/10.1007/s10549-020-05991-x |
Ejemplares similares
-
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
por: de Groot, Stefanie, et al.
Publicado: (2020) -
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, Stefanie, et al.
Publicado: (2019) -
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015) -
Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer
por: Lugtenberg, Rieneke T., et al.
Publicado: (2023) -
Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, Stefanie, et al.
Publicado: (2016)